IL187105A0 - Novel compunds as glp-i agonists - Google Patents
Novel compunds as glp-i agonistsInfo
- Publication number
- IL187105A0 IL187105A0 IL187105A IL18710507A IL187105A0 IL 187105 A0 IL187105 A0 IL 187105A0 IL 187105 A IL187105 A IL 187105A IL 18710507 A IL18710507 A IL 18710507A IL 187105 A0 IL187105 A0 IL 187105A0
- Authority
- IL
- Israel
- Prior art keywords
- glp
- agonists
- compunds
- novel
- novel compunds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN558MU2005 | 2005-05-05 | ||
IN645MU2005 | 2005-05-31 | ||
PCT/IN2006/000154 WO2007017892A2 (en) | 2005-05-05 | 2006-05-04 | Novel compounds as glp-i agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IL187105A0 true IL187105A0 (en) | 2008-02-09 |
Family
ID=37727716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL187105A IL187105A0 (en) | 2005-05-05 | 2007-11-01 | Novel compunds as glp-i agonists |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1891106A2 (no) |
JP (1) | JP2008540402A (no) |
KR (1) | KR20080021636A (no) |
AP (1) | AP2007004227A0 (no) |
AU (1) | AU2006277557A1 (no) |
BR (1) | BRPI0612471A2 (no) |
CA (1) | CA2606894A1 (no) |
EA (1) | EA200702419A1 (no) |
IL (1) | IL187105A0 (no) |
MX (1) | MX2007013655A (no) |
NO (1) | NO20075618L (no) |
WO (1) | WO2007017892A2 (no) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
US20100022457A1 (en) | 2006-05-26 | 2010-01-28 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
DK2084182T3 (da) * | 2006-10-03 | 2013-11-04 | Cadila Healthcare Ltd | Antidiabetiske forbindelser |
CA2707132A1 (en) * | 2007-12-11 | 2009-06-18 | F. Hoffmann-La Roche Ag | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
CA2707448C (en) | 2007-12-11 | 2014-10-14 | Cadila Healthcare Limited | Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities |
CA2759468A1 (en) * | 2009-05-01 | 2010-11-04 | F. Hoffmann-La Roche Ag | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
CN101891823B (zh) | 2010-06-11 | 2012-10-03 | 北京东方百泰生物科技有限公司 | 一种Exendin-4及其类似物融合蛋白 |
EP2956160B1 (en) * | 2013-02-15 | 2018-04-25 | Mayo Foundation For Medical Education And Research | Insulin secreting polypeptides |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
GB0024428D0 (en) * | 2000-10-05 | 2000-11-22 | King S College | Absorption enhancers |
DE60228972D1 (de) * | 2001-07-31 | 2008-10-30 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
BR0306706A (pt) * | 2002-01-08 | 2007-03-27 | Lilly Co Eli | peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica |
WO2005077072A2 (en) * | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
TW200611704A (en) * | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
DE102004043153B4 (de) * | 2004-09-03 | 2013-11-21 | Philipps-Universität Marburg | Erfindung betreffend GLP-1 und Exendin |
-
2006
- 2006-05-04 MX MX2007013655A patent/MX2007013655A/es not_active Application Discontinuation
- 2006-05-04 AU AU2006277557A patent/AU2006277557A1/en not_active Abandoned
- 2006-05-04 BR BRPI0612471A patent/BRPI0612471A2/pt not_active IP Right Cessation
- 2006-05-04 EA EA200702419A patent/EA200702419A1/ru unknown
- 2006-05-04 AP AP2007004227A patent/AP2007004227A0/xx unknown
- 2006-05-04 EP EP06809915A patent/EP1891106A2/en not_active Withdrawn
- 2006-05-04 JP JP2008509578A patent/JP2008540402A/ja not_active Withdrawn
- 2006-05-04 WO PCT/IN2006/000154 patent/WO2007017892A2/en active Application Filing
- 2006-05-04 KR KR1020077028300A patent/KR20080021636A/ko not_active Application Discontinuation
- 2006-05-04 CA CA002606894A patent/CA2606894A1/en not_active Abandoned
-
2007
- 2007-11-01 IL IL187105A patent/IL187105A0/en unknown
- 2007-11-06 NO NO20075618A patent/NO20075618L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AP2007004227A0 (en) | 2007-12-31 |
KR20080021636A (ko) | 2008-03-07 |
BRPI0612471A2 (pt) | 2016-09-06 |
MX2007013655A (es) | 2008-01-24 |
CA2606894A1 (en) | 2007-02-15 |
EA200702419A1 (ru) | 2008-04-28 |
WO2007017892A2 (en) | 2007-02-15 |
AU2006277557A1 (en) | 2007-02-15 |
NO20075618L (no) | 2008-01-30 |
WO2007017892A3 (en) | 2007-09-20 |
EP1891106A2 (en) | 2008-02-27 |
JP2008540402A (ja) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1939202A4 (en) | NEW COMPOUND OF ADENINE | |
EP1939201A4 (en) | NEW ADENINE CONNECTION | |
EP1939198A4 (en) | NEW ADENINE CONNECTION | |
EP1939199A4 (en) | NEW ADENINE CONNECTION | |
EP1939200A4 (en) | NEW ADENINE CONNECTION | |
IL229521A0 (en) | A new preparation | |
EP2089034A4 (en) | NEW USES | |
HK1116776A1 (en) | Triazolophthalazines as pde2-inhibitors | |
IL185901A0 (en) | Novel composition | |
GB0619060D0 (en) | Novel process | |
EP1985234A4 (en) | LANCET | |
IL187105A0 (en) | Novel compunds as glp-i agonists | |
HK1128396A1 (en) | Lancet | |
GB0708226D0 (en) | Y-receptor agonists | |
ZA200903656B (en) | Novel composition | |
GB0601695D0 (en) | Lancet | |
GB0505760D0 (en) | Novel composition | |
GB0621329D0 (en) | Novel composition | |
SI1981972T1 (sl) | Nov postopek | |
GB2425534A8 (en) | Epsilon poly-L-lysine-nucleic acid complex | |
GB0625275D0 (en) | Novel process | |
EP1933850A4 (en) | APTAMERS AS AGONISTS | |
ZA200709471B (en) | Novel compounds as GLP-I agonists | |
GB0815503D0 (en) | Rapid fit extension arm | |
GB0513367D0 (en) | Novel composition |